Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020
Controlled Human Infection With Bordetella pertussis Induces Asymptomatic, Immunizing Colonization.
Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03751514 (A Human Controlled Infection Study to Establish a Safe, Reproducible and Practical Human Bordetella Pertussis Colonisation Model for the Identification of Correlates of Protection Against Colonisation), which is not on this map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Human Controlled Infection Study to Establish a Safe, Reproducible and Practical Human Bordetella Pertussis Colonisation Model for the Identification of Correlates of Protection Against Colonisation (BPCCS)
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Whole-cell pertussis vaccine in early infancy for the prevention of allergy in children.The Cochrane database of systematic reviews · 2021Pooled it
- Distinct early cellular kinetics in participants protected against colonization upon Bordetella pertussis challenge.The Journal of clinical investigation · 2023Trial
- The impact of multiplex panel testing on ascertainment of pertussis-attributable, non-infant deaths: national surveillance from England.Journal of clinical microbiology · 2026Article
- Alternative approaches to phase III clinical trials for vaccine efficacy and licensure: the role of real-world evidence - a meeting report.Biologicals : journal of the International Association of Biological Standardization · 2026Article
- Pre-existing antibodies predict protection while mucosal inflammation correlates with symptomaticmedRxiv : the preprint server for health sciences · 2026Article
- A controlled human infection model for symptomatic pertussis in North America using the pertactin-producing clinical isolate D420.medRxiv : the preprint server for health sciences · 2026Article
- Development of High-Throughput Serum Bactericidal Assays forVaccines · 2026Article
- BPZE1 vaccination induces IL-17NPJ vaccines · 2026Article
- An old foe comes swooping back: Whooping cough resurgence-Okay, now what?PLoS pathogens · 2026Article
- Resurgence of pertussis: Epidemiological trends, contributing factors, challenges, and recommendations for vaccination and surveillance.Human vaccines & immunotherapeutics · 2025Review
- Natural immune boosting biases pertussis infection estimates in seroprevalence studies.Nature communications · 2025Article
- Advocating mucosal immunization: A global need in a viewpoint from China.Innovation (Cambridge (Mass.)) · 2025Review
- Limited response of primary nasal epithelial cells toMicrobiology spectrum · 2025Article
- Highlights of the 14th InternationalmSphere · 2025Article
- A role for genomics-based studies of Bordetella pertussis adaptation.Current opinion in infectious diseases · 2025Review
- Article
- Risk analysis for outpatient experimental infection as a pathway for affordable RSV vaccine development.NPJ vaccines · 2025Article
- Th1 polarization in Bordetella pertussis vaccine responses is maintained through a positive feedback loop.Nature communications · 2025Article
- Symptoms and adverse events in controlled human infection models.Frontiers in medicine · 2025Review
- Advancing European paediatric research - the contribution of the Innovative Health Initiative.Frontiers in medicine · 2025Article
Corrections and comments
- Commented on by
Authors and funding
13 authors at 8 institutions in 3 countries.
Funding
Abstract
backgroundBordetella pertussis is among the leading causes of vaccine-preventable deaths and morbidity globally. Human asymptomatic carriage as a reservoir for community transmission of infections might be a target of future vaccine strategies, but has not been demonstrated. Our objective was to demonstrate that asymptomatic nasopharyngeal carriage of Bordetella pertussis is inducible in humans and to define the microbiological and immunological features of presymptomatic infection.
methodsHealthy subjects aged 18-45 years with an antipertussis toxin immunoglobin G (IgG) concentration of <20 international units/ml were inoculated intranasally with nonattenuated, wild-type Bordetella pertussis strain B1917. Safety, colonization, and shedding were monitored over 17 days in an inpatient facility. Colonization was assessed by culture and quantitative polymerase chain reaction. Azithromycin was administered from Day 14. The inoculum dose was escalated, aiming to colonize at least 70% of participants. Immunological responses were measured.
resultsThere were 34 participants challenged, in groups of 4 or 5. The dose was gradually escalated from 103 colony-forming units (0% colonized) to 105 colony-forming units (80% colonized). Minor symptoms were reported in a minority of participants. Azithromycin eradicated colonization in 48 hours in 88% of colonized individuals. Antipertussis toxin IgG seroconversion occurred in 9 out of 19 colonized participants and in none of the participants who were not colonized. Nasal wash was a more sensitive method to detect colonization than pernasal swabs. No shedding of Bordetella pertussis was detected in systematically collected environmental samples.
conclusionsBordetella pertussis colonization can be deliberately induced and leads to a systemic immune response without causing pertussis symptoms. CLINICAL TRIALS REGISTRATION: NCT03751514.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.